|
시장보고서
상품코드
2128406
통증 관리 의약품 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Pain Management Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
통증 관리 의약품 시장 성장요인
세계 통증 관리 의약품 시장은 2025년에 740억 2,000만 달러 규모에 달했으며, 2026년의 775억 8,000만 달러에서 2034년까지 1,171억 8,000만 달러로 성장하여, 예측 기간 동안 연평균 성장률(CAGR)은 5.29%에 달할 것으로 전망됩니다. 2025년에는 북미가 시장을 주도하며 전 세계 시장 점유율의 47.59%를 차지했습니다. 이는 선진적인 의료 인프라, 높은 처방량, 그리고 혁신적인 비오피오이드계 통증 치료법의 채택 확대에 힘입은 결과입니다.
통증 관리 의약품은 관절염, 신경병성 통증, 편두통, 암성 통증, 섬유근통, 근골격계 질환, 수술 후 회복 등과 관련된 급성 및 만성 통증을 완화하는 데 사용됩니다. 만성 통증 유병률의 상승, 세계 인구의 고령화, 수술 건수의 증가, 그리고 효과적인 통증 치료에 대한 인식 제고가 시장 확장을 지속적으로 뒷받침하고 있습니다. 동시에, 제약사들은 오피오이드 의존 및 남용에 대한 우려를 해소하기 위해 더 안전한 비오피오이드 치료법 개발에 주력하고 있습니다.
시장 동향
통증 관리 의약품 시장을 형성하는 가장 중요한 동향 중 하나는 다각적인 통증 관리 전략의 채택이 증가하고 있다는 점입니다. 의료 종사자들은 NSAIDs, 아세트아미노펜, 국소 마취제, 항경련제, 항우울제, 비오피오이드계 진통제 등 여러 약물 군을 조합하여 오피오이드 사용을 최소화하면서 통증 관리를 개선하고 있습니다.
오피오이드 사용을 억제하는 치료법에 대한 임상 현장의 수요가 증가함에 따라, 제약사들은 여러 통증 전달 경로를 표적으로 하는 혁신적인 제품에 대한 투자를 적극적으로 추진하고 있습니다. 또한, 외용 젤, 패치, 주사제 등의 국소 치료법 사용이 확대됨에 따라 전신성 부작용을 줄이면서 환자의 치료 성과가 향상되고 있습니다.
시장 촉진요인
이 시장의 주요 촉진요인은 만성 통증 질환으로 인한 전 세계적 부담의 증가입니다. 관절염, 만성 요통, 편두통, 신경병성 통증, 섬유근통, 암 관련 통증 등의 질환은 장기적인 치료가 필요하기 때문에 처방약 및 일반의약품 형태의 진통제에 대한 수요가 지속되고 있습니다.
혁신적인 의약품 개발에 대한 투자 확대도 시장 성장을 뒷받침하고 있습니다. 각 제약사는 안전성 프로파일이 개선되고 효과적인 통증 완화를 제공하는 첨단 비오피오이드계 약물을 잇달아 시장에 출시하고 있습니다. 전 세계적으로 수술 건수가 증가하고 있어, 병원 및 외래 진료 현장에서 수술 후 통증 관리 제품에 대한 수요가 더욱 높아지고 있습니다.
시장 제약요인
긍정적인 성장 전망이 있는 반면, 오피오이드의 안전성에 대한 우려와 특정 진통제에 수반되는 장기적인 부작용으로 인해 시장은 제약에 직면해 있습니다. 오피오이드 계열 약물은 심한 통증에 대해 여전히 높은 효과를 발휘하지만, 의존성, 오용, 중독 및 과다 복용의 위험이 따릅니다.
마찬가지로, NSAID의 장기 사용은 심혈관계 및 소화기계 합병증을 증가시킬 가능성이 있어, 의사들은 보다 신중한 처방을 하도록 권고받고 있습니다. 규제 당국은 안전 지침을 지속적으로 강화하고 있어, 기존 오피오이드 요법의 장기적인 성장을 제한하고 있습니다.
시장 기회
국소 및 국소적 통증 관리 요법에 대한 수요 확대는 큰 성장 기회를 가져오고 있습니다. 진통 젤, 스프레이, 크림, 경피 패치, 국소용 비오피오이드 제제 등의 제품은 전신 노출을 줄이면서 표적에 맞춘 치료를 제공합니다.
고령 환자나 여러 만성 질환을 앓고 있는 사람들 사이에서 편의성이 높고 비침습적인 치료법에 대한 선호도가 높아짐에 따라, 각 제약사는 외용 진통제 제품 라인업을 확대하고 있습니다. 또한, 편두통에 특화된 치료법이나 차세대 비오피오이드계 진통제의 개발이 지속된다면 새로운 수익 기회가 창출될 것으로 예상됩니다.
시장의 과제
이 시장이 직면한 주요 과제 중 하나는 오피오이드계 의약품을 둘러싼 엄격한 규제 환경입니다. 정부 및 의료 기관은 오피오이드 남용을 줄이기 위해 더욱 엄격한 처방 지침, 안전성 표시 강화, 그리고 모니터링 프로그램 도입을 지속하고 있습니다.
더 안전한 대체 약물을 개발하려면 광범위한 임상 연구, 규제 당국의 승인, 그리고 막대한 투자가 필요하며, 제품 개발에는 시간과 비용이 소요됩니다. 제약 기업은 경쟁을 피하기 위해 혁신과 엄격한 안전 요건 사이의 균형을 맞춰야 합니다.
세분화 분석
약제 분류별
NSAID(비스테로이드성 항염증제) 부문은 관절염, 근골격계 질환, 요통, 수술 후 통증 및 기타 급성 통증 치료에 널리 사용되고 있어 2025년에 가장 큰 시장 점유율을 차지했습니다. 처방약 및 일반 의약품 모두로 구할 수 있다는 점이 전 세계 수요의 견조함을 지속적으로 뒷받침하고 있습니다.
편두통 치료제 부문은 진단율 상승, 인지도 향상, 그리고 혁신적인 편두통 치료법의 지속적인 도입에 힘입어 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예상됩니다.
통증 유형별
2025년에는 관절염, 신경성 통증, 편두통, 섬유근통, 만성 요통, 암성 통증 등 장기간 지속되는 질환의 경우 지속적인 치료와 반복적인 처방이 필요하기 때문에 만성 통증 부문이 시장을 주도했습니다.
급성 통증 부문은 수술, 외상 치료 및 응급 상황에서의 통증 관리 증가에 힘입어 꾸준한 성장이 예상됩니다.
약제 종류별
처방약 부문은 만성 통증, 편두통, 암성 통증, 신경병성 통증 및 수술 후 회복을 위한 의사 처방 요법의 가격이 고가인 탓에 계속해서 최대 수익원으로 자리매김했습니다.
한편, OTC(일반의약품) 진통제는 편의성과 소매 약국에서 쉽게 구할 수 있다는 점 덕분에 계속해서 높은 판매량을 유지하고 있습니다.
지역별 전망
북미는 견조한 의료비 지출, 만성 통증 질환의 높은 유병률, 그리고 혁신적인 비오피오이드 요법의 급속한 보급에 힘입어 2025년에는 352억 3,000만 달러의 시장 규모로 세계 시장을 선도했습니다.
유럽은 고령화, 근골격계 질환의 증가, 그리고 보다 안전한 통증 관리 방법에 대한 선호도 증가에 힘입어 계속해서 2위 지역 시장을 차지하고 있습니다.
아시아태평양에서는 의료 서비스 접근성 향상, 제약 산업의 확대, 그리고 만성 통증 질환 진단 건수 증가가 중국, 일본, 인도 및 기타 신흥 경제국에서의 수요를 끌어올려 견조한 성장이 예상됩니다. 라틴아메리카, 중동 및 아프리카도 의료 인프라 개선과 진통제 접근성 향상으로 인해 꾸준한 성장이 예상됩니다.
최근 업계 동향으로는 2026년 6월 애브비(AbbVie)사의 ‘AQUIPTA’가 유럽집행위원회로부터 승인을 받은 점, 2026년 4월 엘리트 파마슈티컬스(Elite Pharmaceuticals)사가 메타돈 정제의 제네릭 의약품을 출시한 점, 히크마 파마슈티컬스(Hikma Pharmaceuticals)의 제네릭 버전‘누신타’의 2026년 2월 출시, 그리고 토닉스 파마슈티컬스의 섬유근통 치료제 ‘TONMYA’의 2025년 11월 상품화 등이 있으며, 이는 비오피오이드계 및 표적형 통증 치료제 분야의 지속적인 혁신을 반영하고 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 통증 관리 의약품 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.09.16Growth Factors of pain management drugs Market
The global pain management drugs market was valued at USD 74.02 billion in 2025 and is projected to grow from USD 77.58 billion in 2026 to USD 117.18 billion by 2034, registering a CAGR of 5.29% during the forecast period. North America dominated the market in 2025, accounting for 47.59% of the global market share, supported by advanced healthcare infrastructure, high prescription volumes, and increasing adoption of innovative non-opioid pain therapies.
Pain management drugs are used to relieve acute and chronic pain associated with conditions such as arthritis, neuropathic pain, migraine, cancer pain, fibromyalgia, musculoskeletal disorders, and post-operative recovery. Rising prevalence of chronic pain, an aging global population, increasing surgical procedures, and growing awareness of effective pain treatment continue to support market expansion. At the same time, pharmaceutical companies are focusing on developing safer, non-opioid therapies to address concerns surrounding opioid dependence and misuse.
Market Trends
One of the most significant trends shaping the pain management drugs market is the increasing adoption of multimodal pain management strategies. Healthcare providers are combining multiple drug classes-including NSAIDs, acetaminophen, local anesthetics, anticonvulsants, antidepressants, and non-opioid analgesics-to improve pain control while minimizing opioid use.
The growing clinical preference for opioid-sparing therapies has encouraged pharmaceutical companies to invest in innovative products that target multiple pain pathways. In addition, expanding use of localized treatments such as topical gels, patches, and injectable therapies is improving patient outcomes while reducing systemic side effects.
Market Drivers
The major driver of the market is the rising global burden of chronic pain disorders. Conditions including arthritis, chronic back pain, migraine, neuropathic pain, fibromyalgia, and cancer-related pain require long-term treatment, resulting in sustained demand for both prescription and over-the-counter analgesics.
Growing investments in innovative drug development are also fueling market growth. Pharmaceutical companies continue introducing advanced non-opioid medications that provide effective pain relief with improved safety profiles. Rising numbers of surgeries worldwide further increase the need for post-operative pain management products across hospitals and outpatient settings.
Market Restraints
Despite favorable growth prospects, the market faces restraints due to opioid safety concerns and long-term adverse effects associated with certain analgesics. Opioid medications remain highly effective for severe pain but are associated with dependence, misuse, addiction, and overdose risks.
Similarly, prolonged use of NSAIDs may increase cardiovascular and gastrointestinal complications, prompting physicians to adopt more cautious prescribing practices. Regulatory authorities continue strengthening safety guidelines, limiting long-term growth of traditional opioid therapies.
Market Opportunities
The expanding demand for topical and localized pain management therapies presents significant growth opportunities. Products such as pain relief gels, sprays, creams, transdermal patches, and localized non-opioid formulations provide targeted treatment while reducing systemic exposure.
Increasing preference for convenient, non-invasive treatment options among elderly patients and individuals managing multiple chronic conditions is encouraging manufacturers to expand their topical pain relief portfolios. Furthermore, continued development of migraine-specific therapies and next-generation non-opioid analgesics is expected to create new revenue opportunities.
Market Challenges
One of the primary challenges facing the market is the strict regulatory environment surrounding opioid-based medications. Governments and healthcare agencies continue implementing tighter prescribing guidelines, enhanced safety labeling, and monitoring programs to reduce opioid misuse.
Developing safer alternatives requires extensive clinical research, regulatory approval, and significant investment, making product development both time-consuming and costly. Pharmaceutical companies must balance innovation with stringent safety requirements to remain competitive.
Segmentation Analysis
By Drug Class
The NSAIDs segment accounted for the largest market share in 2025 due to their widespread use in treating arthritis, musculoskeletal disorders, back pain, post-operative pain, and other acute pain conditions. Their availability as both prescription and over-the-counter medications continues to support strong global demand.
The anti-migraine drugs segment is projected to record the fastest growth during the forecast period, driven by increasing diagnosis rates, improved awareness, and continued introduction of innovative migraine therapies.
By Pain Type
The chronic pain segment dominated the market in 2025 as long-term conditions such as arthritis, neuropathic pain, migraine, fibromyalgia, chronic back pain, and cancer pain require continuous treatment and repeated prescriptions.
The acute pain segment is expected to witness steady growth, supported by increasing surgical procedures, trauma care, and emergency pain management.
By Drug Type
The prescription drugs segment remained the largest revenue contributor due to the high value of physician-prescribed therapies for chronic pain, migraine, cancer pain, neuropathic disorders, and post-operative recovery.
Meanwhile, OTC pain medications continue to maintain high sales volumes due to their convenience and widespread availability through retail pharmacies.
Regional Outlook
North America led the global market with a valuation of USD 35.23 billion in 2025, supported by strong healthcare spending, high prevalence of chronic pain disorders, and rapid adoption of innovative non-opioid therapies.
Europe remains the second-largest regional market, driven by its aging population, increasing musculoskeletal disorders, and growing preference for safer pain management approaches.
Asia Pacific is expected to witness robust growth as rising healthcare access, expanding pharmaceutical industries, and increasing diagnosis of chronic pain conditions boost demand across China, Japan, India, and other emerging economies. Latin America and the Middle East & Africa are also expected to experience steady growth due to improving healthcare infrastructure and greater availability of pain medications.
Competitive Landscape
The global pain management drugs market is moderately fragmented, with leading pharmaceutical companies competing through extensive product portfolios, continuous research and development, strategic acquisitions, and regulatory approvals for innovative therapies. Increasing investment in non-opioid medicines, migraine treatments, localized pain relief products, and generic drug expansion continues to strengthen market competition.
Major companies operating in the market include AbbVie Inc., Haleon plc, Bayer AG, Kenvue Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sanofi, and Grunenthal GmbH.
Recent industry developments include AbbVie's European Commission approval for AQUIPTA in June 2026, Elite Pharmaceuticals' launch of generic methadone tablets in April 2026, Hikma Pharmaceuticals' generic Nucynta launch in February 2026, and Tonix Pharmaceuticals' commercialization of TONMYA for fibromyalgia in November 2025, reflecting continued innovation across non-opioid and targeted pain therapies.
Conclusion
The pain management drugs market is expected to maintain steady growth as the prevalence of chronic pain conditions continues to rise globally. Increasing demand for safer non-opioid therapies, expanding use of multimodal treatment approaches, growing investments in migraine and neuropathic pain medications, and continuous pharmaceutical innovation will remain the key factors driving industry expansion. With the market projected to increase from USD 74.02 billion in 2025 to USD 117.18 billion by 2034, companies that focus on advanced, targeted, and patient-centered pain management solutions are well positioned to capitalize on future growth opportunities.
Segmentation By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Region
By Drug Class * Opioids
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Local Anesthetics
- Anticonvulsants
- Antidepressants
- Anti-migraine Drugs
- Non-opioid/Non-narcotic Analgesics
- Muscle Relaxants
- Others
By Pain Type * Acute Pain
- Chronic Pain
By Drug Type * Prescription
- OTC
By Disease Indication * Neuropathic Pain
- Cancer Pain
- Post-operative Pain
- Arthritis Pain
- Chronic Back Pain
- Migraine
- Fibromyalgia
- Others
By Route of Administration * Oral
- Injectable/Parenteral
- Transdermal
- Topical
- Others
By Age Group * Pediatric
- Adults
By Type * Branded
- Generic
By Distribution Channel * Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region * North America (By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Pain Type, Drug Type, Disease Indication, Route of Administration, Age Group, Type, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Diseases, By Key Regions/ Countries
- 4.2. New Product Launches, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
5. Global Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Opioids
- 5.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 5.1.3. Local Anesthetics
- 5.1.4. Anticonvulsants
- 5.1.5. Antidepressants
- 5.1.6. Anti-migraine Drugs
- 5.1.7. Non-opioid/Non-narcotic Analgesics
- 5.1.8. Muscle Relaxants
- 5.1.9. Others
- 5.2. Market Analysis, Insights and Forecast - By Pain Type
- 5.2.1. Acute Pain
- 5.2.2. Chronic Pain
- 5.3. Market Analysis, Insights and Forecast - By Drug Type
- 5.3.1. Prescription
- 5.3.2. OTC
- 5.4. Market Analysis, Insights and Forecast - By Disease Indication
- 5.4.1. Neuropathic Pain
- 5.4.2. Cancer Pain
- 5.4.3. Post-operative Pain
- 5.4.4. Arthritis Pain
- 5.4.5. Chronic Back Pain
- 5.4.6. Migraine
- 5.4.7. Fibromyalgia
- 5.4.8. Others
- 5.5. Market Analysis, Insights and Forecast - By Route of Administration
- 5.5.1. Oral
- 5.5.2. Injectable/Parenteral
- 5.5.3. Transdermal
- 5.5.4. Topical
- 5.5.5. Others
- 5.6. Market Analysis, Insights and Forecast - By Age Group
- 5.6.1. Pediatric
- 5.6.2. Adults
- 5.7. Market Analysis, Insights and Forecast - By Type
- 5.7.1. Branded
- 5.7.2. Generic
- 5.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.8.1. Hospital Pharmacies
- 5.8.2. Drug Stores & Retail Pharmacies
- 5.8.3. Online Pharmacies
- 5.9. Market Analysis, Insights and Forecast - Region
- 5.9.1. North America
- 5.9.2. Europe
- 5.9.3. Asia Pacific
- 5.9.4. Latin America
- 5.9.5. Middle East & Africa
6. North America Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Opioids
- 6.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 6.1.3. Local Anesthetics
- 6.1.4. Anticonvulsants
- 6.1.5. Antidepressants
- 6.1.6. Anti-migraine Drugs
- 6.1.7. Non-opioid/Non-narcotic Analgesics
- 6.1.8. Muscle Relaxants
- 6.1.9. Others
- 6.2. Market Analysis, Insights and Forecast - By Pain Type
- 6.2.1. Acute Pain
- 6.2.2. Chronic Pain
- 6.3. Market Analysis, Insights and Forecast - By Drug Type
- 6.3.1. Prescription
- 6.3.2. OTC
- 6.4. Market Analysis, Insights and Forecast - By Disease Indication
- 6.4.1. Neuropathic Pain
- 6.4.2. Cancer Pain
- 6.4.3. Post-operative Pain
- 6.4.4. Arthritis Pain
- 6.4.5. Chronic Back Pain
- 6.4.6. Migraine
- 6.4.7. Fibromyalgia
- 6.4.8. Others
- 6.5. Market Analysis, Insights and Forecast - By Route of Administration
- 6.5.1. Oral
- 6.5.2. Injectable/Parenteral
- 6.5.3. Transdermal
- 6.5.4. Topical
- 6.5.5. Others
- 6.6. Market Analysis, Insights and Forecast - By Age Group
- 6.6.1. Pediatric
- 6.6.2. Adults
- 6.7. Market Analysis, Insights and Forecast - By Type
- 6.7.1. Branded
- 6.7.2. Generic
- 6.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.8.1. Hospital Pharmacies
- 6.8.2. Drug Stores & Retail Pharmacies
- 6.8.3. Online Pharmacies
- 6.9. Market Analysis, Insights and Forecast - By Country
- 6.9.1. U.S.
- 6.9.2. Canada
7. Europe Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Opioids
- 7.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 7.1.3. Local Anesthetics
- 7.1.4. Anticonvulsants
- 7.1.5. Antidepressants
- 7.1.6. Anti-migraine Drugs
- 7.1.7. Non-opioid/Non-narcotic Analgesics
- 7.1.8. Muscle Relaxants
- 7.1.9. Others
- 7.2. Market Analysis, Insights and Forecast - By Pain Type
- 7.2.1. Acute Pain
- 7.2.2. Chronic Pain
- 7.3. Market Analysis, Insights and Forecast - By Drug Type
- 7.3.1. Prescription
- 7.3.2. OTC
- 7.4. Market Analysis, Insights and Forecast - By Disease Indication
- 7.4.1. Neuropathic Pain
- 7.4.2. Cancer Pain
- 7.4.3. Post-operative Pain
- 7.4.4. Arthritis Pain
- 7.4.5. Chronic Back Pain
- 7.4.6. Migraine
- 7.4.7. Fibromyalgia
- 7.4.8. Others
- 7.5. Market Analysis, Insights and Forecast - By Route of Administration
- 7.5.1. Oral
- 7.5.2. Injectable/Parenteral
- 7.5.3. Transdermal
- 7.5.4. Topical
- 7.5.5. Others
- 7.6. Market Analysis, Insights and Forecast - By Age Group
- 7.6.1. Pediatric
- 7.6.2. Adults
- 7.7. Market Analysis, Insights and Forecast - By Type
- 7.7.1. Branded
- 7.7.2. Generic
- 7.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.8.1. Hospital Pharmacies
- 7.8.2. Drug Stores & Retail Pharmacies
- 7.8.3. Online Pharmacies
- 7.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.9.1. U.K.
- 7.9.2. Germany
- 7.9.3. France
- 7.9.4. Italy
- 7.9.5. Spain
- 7.9.6. Scandinavia
- 7.9.7. Rest of Europe
8. Asia Pacific Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Opioids
- 8.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 8.1.3. Local Anesthetics
- 8.1.4. Anticonvulsants
- 8.1.5. Antidepressants
- 8.1.6. Anti-migraine Drugs
- 8.1.7. Non-opioid/Non-narcotic Analgesics
- 8.1.8. Muscle Relaxants
- 8.1.9. Others
- 8.2. Market Analysis, Insights and Forecast - By Pain Type
- 8.2.1. Acute Pain
- 8.2.2. Chronic Pain
- 8.3. Market Analysis, Insights and Forecast - By Drug Type
- 8.3.1. Prescription
- 8.3.2. OTC
- 8.4. Market Analysis, Insights and Forecast - By Disease Indication
- 8.4.1. Neuropathic Pain
- 8.4.2. Cancer Pain
- 8.4.3. Post-operative Pain
- 8.4.4. Arthritis Pain
- 8.4.5. Chronic Back Pain
- 8.4.6. Migraine
- 8.4.7. Fibromyalgia
- 8.4.8. Others
- 8.5. Market Analysis, Insights and Forecast - By Route of Administration
- 8.5.1. Oral
- 8.5.2. Injectable/Parenteral
- 8.5.3. Transdermal
- 8.5.4. Topical
- 8.5.5. Others
- 8.6. Market Analysis, Insights and Forecast - By Age Group
- 8.6.1. Pediatric
- 8.6.2. Adults
- 8.7. Market Analysis, Insights and Forecast - By Type
- 8.7.1. Branded
- 8.7.2. Generic
- 8.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.8.1. Hospital Pharmacies
- 8.8.2. Drug Stores & Retail Pharmacies
- 8.8.3. Online Pharmacies
- 8.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.9.1. China
- 8.9.2. Japan
- 8.9.3. India
- 8.9.4. Southeast Asia
- 8.9.5. Australia
- 8.9.6. Rest of Asia Pacific
9. Latin America Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Opioids
- 9.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 9.1.3. Local Anesthetics
- 9.1.4. Anticonvulsants
- 9.1.5. Antidepressants
- 9.1.6. Anti-migraine Drugs
- 9.1.7. Non-opioid/Non-narcotic Analgesics
- 9.1.8. Muscle Relaxants
- 9.1.9. Others
- 9.2. Market Analysis, Insights and Forecast - By Pain Type
- 9.2.1. Acute Pain
- 9.2.2. Chronic Pain
- 9.3. Market Analysis, Insights and Forecast - By Drug Type
- 9.3.1. Prescription
- 9.3.2. OTC
- 9.4. Market Analysis, Insights and Forecast - By Disease Indication
- 9.4.1. Neuropathic Pain
- 9.4.2. Cancer Pain
- 9.4.3. Post-operative Pain
- 9.4.4. Arthritis Pain
- 9.4.5. Chronic Back Pain
- 9.4.6. Migraine
- 9.4.7. Fibromyalgia
- 9.4.8. Others
- 9.5. Market Analysis, Insights and Forecast - By Route of Administration
- 9.5.1. Oral
- 9.5.2. Injectable/Parenteral
- 9.5.3. Transdermal
- 9.5.4. Topical
- 9.5.5. Others
- 9.6. Market Analysis, Insights and Forecast - By Age Group
- 9.6.1. Pediatric
- 9.6.2. Adults
- 9.7. Market Analysis, Insights and Forecast - By Type
- 9.7.1. Branded
- 9.7.2. Generic
- 9.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.8.1. Hospital Pharmacies
- 9.8.2. Drug Stores & Retail Pharmacies
- 9.8.3. Online Pharmacies
- 9.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.9.1. Brazil
- 9.9.2. Mexico
- 9.9.3. Rest of Latin America
10. Middle East & Africa Pain Management Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Opioids
- 10.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 10.1.3. Local Anesthetics
- 10.1.4. Anticonvulsants
- 10.1.5. Antidepressants
- 10.1.6. Anti-migraine Drugs
- 10.1.7. Non-opioid/Non-narcotic Analgesics
- 10.1.8. Muscle Relaxants
- 10.1.9. Others
- 10.2. Market Analysis, Insights and Forecast - By Pain Type
- 10.2.1. Acute Pain
- 10.2.2. Chronic Pain
- 10.3. Market Analysis, Insights and Forecast - By Drug Type
- 10.3.1. Prescription
- 10.3.2. OTC
- 10.4. Market Analysis, Insights and Forecast - By Disease Indication
- 10.4.1. Neuropathic Pain
- 10.4.2. Cancer Pain
- 10.4.3. Post-operative Pain
- 10.4.4. Arthritis Pain
- 10.4.5. Chronic Back Pain
- 10.4.6. Migraine
- 10.4.7. Fibromyalgia
- 10.4.8. Others
- 10.5. Market Analysis, Insights and Forecast - By Route of Administration
- 10.5.1. Oral
- 10.5.2. Injectable/Parenteral
- 10.5.3. Transdermal
- 10.5.4. Topical
- 10.5.5. Others
- 10.6. Market Analysis, Insights and Forecast - By Age Group
- 10.6.1. Pediatric
- 10.6.2. Adults
- 10.7. Market Analysis, Insights and Forecast - By Type
- 10.7.1. Branded
- 10.7.2. Generic
- 10.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.8.1. Hospital Pharmacies
- 10.8.2. Drug Stores & Retail Pharmacies
- 10.8.3. Online Pharmacies
- 10.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.9.1. GCC
- 10.9.2. South Africa
- 10.9.3. Rest of the Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. AbbVie Inc.
- 11.2.2. Haleon plc
- 11.2.3. Bayer AG
- 11.2.4. Kenvue Inc.
- 11.2.5. Pfizer Inc.
- 11.2.6. Eli Lilly and Company
- 11.2.7. Teva Pharmaceutical Industries Ltd.
- 11.2.8. Viatris Inc.
- 11.2.9. Sanofi
- 11.2.10. Grunenthal GmbH
